CN120058926A - 与瓜氨酸化的组蛋白2a和/或4结合的抗体 - Google Patents

与瓜氨酸化的组蛋白2a和/或4结合的抗体 Download PDF

Info

Publication number
CN120058926A
CN120058926A CN202510240710.XA CN202510240710A CN120058926A CN 120058926 A CN120058926 A CN 120058926A CN 202510240710 A CN202510240710 A CN 202510240710A CN 120058926 A CN120058926 A CN 120058926A
Authority
CN
China
Prior art keywords
seq
antibody
binding fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510240710.XA
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·玛丽亚·亨德里克·拉茨
雷纳托·赫拉尔杜斯·西尔瓦诺·奇里维
约翰内斯·威廉姆斯·赫拉尔杜斯·范罗斯马伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chitrell Private Ltd
Original Assignee
Chitrell Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1813597.0A external-priority patent/GB201813597D0/en
Priority claimed from GBGB1900983.6A external-priority patent/GB201900983D0/en
Application filed by Chitrell Private Ltd filed Critical Chitrell Private Ltd
Publication of CN120058926A publication Critical patent/CN120058926A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202510240710.XA 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体 Pending CN120058926A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1813597.0 2018-08-21
GBGB1813597.0A GB201813597D0 (en) 2018-08-21 2018-08-21 Antibody
GB1900983.6 2019-01-24
GBGB1900983.6A GB201900983D0 (en) 2019-01-24 2019-01-24 Antibody
PCT/EP2019/072302 WO2020038963A1 (en) 2018-08-21 2019-08-20 Antibodies binding to citrullinated histone 2a and/or 4
CN201980070130.3A CN112930356B (zh) 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980070130.3A Division CN112930356B (zh) 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体

Publications (1)

Publication Number Publication Date
CN120058926A true CN120058926A (zh) 2025-05-30

Family

ID=67688785

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510240710.XA Pending CN120058926A (zh) 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体
CN201980070130.3A Active CN112930356B (zh) 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980070130.3A Active CN112930356B (zh) 2018-08-21 2019-08-20 与瓜氨酸化的组蛋白2a和/或4结合的抗体

Country Status (21)

Country Link
US (3) US20210395350A1 (https=)
EP (2) EP3841120B1 (https=)
JP (2) JP7434328B2 (https=)
KR (2) KR20250148711A (https=)
CN (2) CN120058926A (https=)
AU (3) AU2019326740B2 (https=)
CA (1) CA3110013A1 (https=)
DK (1) DK3841120T3 (https=)
ES (1) ES3048210T3 (https=)
FI (1) FI3841120T3 (https=)
HR (1) HRP20251346T1 (https=)
IL (2) IL280995B2 (https=)
LT (1) LT3841120T (https=)
MX (3) MX2025007881A (https=)
PT (1) PT3841120T (https=)
RS (1) RS67385B1 (https=)
SG (1) SG11202101652PA (https=)
SI (1) SI3841120T1 (https=)
SM (1) SMT202500388T1 (https=)
WO (1) WO2020038963A1 (https=)
ZA (1) ZA202101051B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
WO2021209465A1 (en) * 2020-04-14 2021-10-21 Universiteit Maastricht Peptide for the treatment of net-associated diseases
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
GB202012326D0 (en) 2020-08-07 2020-09-23 Citryll B V Diagnostic
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) * 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody
JP7037940B2 (ja) * 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
US20170038381A1 (en) 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
CN117396221A (zh) * 2021-05-04 2024-01-12 奇特里尔私人有限公司 嗜酸性粒细胞陷阱的抑制
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제

Also Published As

Publication number Publication date
IL322482A (en) 2025-09-01
CN112930356A (zh) 2021-06-08
IL280995B1 (en) 2025-09-01
US12590143B2 (en) 2026-03-31
JP2024059670A (ja) 2024-05-01
HRP20251346T1 (hr) 2025-12-19
EP4659807A3 (en) 2026-03-18
JP2021535211A (ja) 2021-12-16
IL280995A (en) 2021-04-29
AU2019326740B2 (en) 2025-11-27
LT3841120T (lt) 2025-11-10
ES3048210T3 (en) 2025-12-09
US20210395350A1 (en) 2021-12-23
RS67385B1 (sr) 2025-11-28
WO2020038963A1 (en) 2020-02-27
AU2026201302A1 (en) 2026-03-12
EP4659807A2 (en) 2025-12-10
MX2025007881A (es) 2025-08-01
ZA202101051B (en) 2022-08-31
KR102871821B1 (ko) 2025-10-16
SI3841120T1 (sl) 2025-12-31
CN112930356B (zh) 2025-03-21
FI3841120T3 (fi) 2025-11-03
AU2019326740A1 (en) 2021-03-18
KR20210056355A (ko) 2021-05-18
EP3841120A1 (en) 2021-06-30
DK3841120T3 (da) 2025-10-20
US20230183327A1 (en) 2023-06-15
KR20250148711A (ko) 2025-10-14
MX2021001902A (es) 2021-05-27
CA3110013A1 (en) 2020-02-27
IL280995B2 (en) 2026-01-01
US20210403543A1 (en) 2021-12-30
AU2026201303A1 (en) 2026-03-12
SG11202101652PA (en) 2021-03-30
PT3841120T (pt) 2025-10-20
JP7434328B2 (ja) 2024-02-20
EP3841120B1 (en) 2025-09-24
MX2025007882A (es) 2025-08-01
JP7835788B2 (ja) 2026-03-25
US11345750B2 (en) 2022-05-31
SMT202500388T1 (it) 2025-11-10

Similar Documents

Publication Publication Date Title
CN112930356B (zh) 与瓜氨酸化的组蛋白2a和/或4结合的抗体
CN106459215A (zh) 治疗自身免疫疾病的结合fcrn的抗体
US20250084154A1 (en) Inhibition of eosinophilic traps
CA3148562A1 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4
CN117396221A (zh) 嗜酸性粒细胞陷阱的抑制
EA048367B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
EA053252B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
EA052640B1 (ru) Ингибирование внеклеточных ловушек
WO2025120152A1 (en) Diagnostic agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination